Abstract
Background Second-generation antipsychotics (SGAs) are commonly used to treat schizophrenia (SCZ), but SGAs may differ in the severity of side effects. Previous observational studies had limitations like failing to account for confounding factors and short follow-up periods. This study compared the long-term metabolic and anthropometric side effects of seven second-generation antipsychotics (SGAs) in a Chinese schizophrenia population, using a within-subject approach to reduce risk of confounding.
Methods Longitudinal data on SGA prescriptions, concomitant medications, fasting blood glucose, lipid profiles, and BMI were collected from 767 schizophrenia patients, with follow-up up to 18.7 years (median ∼6.2 years). Linear mixed models estimated the effects of SGAs, as binary predictors and by dosage, on metabolic profiles.
Results When considering SGAs as binary predictors, clozapine and olanzapine were associated with the most substantial worsening of lipid profiles and BMI, while clozapine alone showed a significant increase in blood glucose. Amisulpride, paliperidone, and quetiapine worsened lipid profiles and increased BMI. Conversely, aripiprazole improved lipid profiles but slightly increased BMI. Examining dosage effects showed consistent results overall. At minimum effective doses, clozapine had the most severe metabolic side effects, followed by olanzapine. Risperidone and aripiprazole had the least metabolic impact, with aripiprazole significantly lowering lipids.
Conclusions This study clarified the long-term, dose-dependent metabolic and anthropometric effects of different SGAs in Chinese schizophrenia patients. Our findings may inform clinicians and SCZ patients of SGA choices.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Health and Medical Research Fund (HCS, grant number 06170506). The views expressed are those of the authors and not necessarily those of the Health Bureau of HKSAR. This work was also partially supported by the KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research of Common Diseases, the Hong Kong Branch of the Chinese Academy of Sciences Center for Excellence in Animal Evolution and Genetics, and a National Natural Science Foundation of China grant (HCS, grant number 81971706); the HKU Seed Fund for Basic Research for New Staff (SYL, grant number 202009185071); the HKU Enhanced Start-up Fund for New Staff (SYL); Suen Chi-Sun Endowed Professorship in Clinical Science at The University of Hong Kong (PCS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures involving human subjects/patients were approved by the ethics committees of the New Territories West Cluster (reference number: NTWC/CREC/823/10; NTWC/CREC/1293/14) and the Chinese University of Hong Kong and the New Territories East Cluster (reference number: 2016.559).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
1.Cite more references to support the difference in the prevalence of BMI and metabolic syndrome between Chinese and Western populations. 2.In the results section, include a description of the 95% confidence interval for the effect size. 3.Rephrase some sentences to improve their readability.
Data Availability
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to their containing information that could compromise the privacy of research participants.
